CLSD - Earnings call transcript Q2 2021 | Clearside Biomedical, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day everyone and thank you for standing by. Welcome to the Clearside Biomedical Second Quarter of 2021 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode. [Operator Instructions] And please be advised that today’s conference is being recorded. [Operator Instructions] I would now like to hand the conference over to your speaker today, Ms. Relations. Investor Clearside Kobin, Jenny Please go ahead.

Jenny Kobin

and Good on for us you call afternoon, today. everyone, the joining thank

Before I certain a Securities the result results Factors these filings as XX, today's Actual SEC call prospects report available other call, XXXX. differ remarks forward-looking those for we constitute including December that those materially section of we XX-K and year Litigation about the we you annual Risk various by begin, indicated that of for on expectations, discussed may will Reform would from the like forward-looking our on the company's Act our be factors, plans during Form statements Private our making XXXX, ended make forward-looking future important statements in of Various website. remind statements. this to and during of purposes

represent any should upon be relied forward-looking addition, today any of date. In our of and statements views not as subsequent representing our as as views

While disclaim any update we specifically our do Lasezkay, even so call, have future, to views George these in if the we may our forward-looking On obligation we today's statements elect change. to and Dr. our remarks, Officer; Executive the we Medical Officer; Chief our Officer Ciulla, Deignan, our and open Charlie Chief your Chief Development After questions. Chief for Officer. call Financial Thomas formal will

that website from today, During webcast. as CLS-AX discuss last of announced for X Cohort this results available Phase Slides Ciulla on our data our earnings clinical related key supporting are our Dr. for we call the to month. X/Xa trial will call materials this

George. to over call the turn to like I’d Now,

George Lasezkay

call you for today. and Thank you, us joining thank Jenny. on Good everyone the afternoon

review ophthalmic clinical several as position suprachoroidal and in AMD recent the continue from CLS-AX FDA results XIPERE drug wet space clinical different with new demonstrated trials our multiple We our under for trial. application leader positive currently to the in indications, our

of designed clinical unlock are to non-surgical, the repeatable the technology tested benefits develop administering the suprachoroidal company clinically space. drugs micro-injection to We first into potential a

covering over Internally, SCS therapeutic our as the We capabilities into as patents molecule patents has well our our proprietary to small suspensions space. which delivery includes the existing proprietary into of for team transform the suprachoroidal with research have protect eye our Microinjector, proven suprachoroidal delivery global to to XX diseases. drugs agents into target platform space technology, the back

FDA uveitis, a first ever action be Canada Our uveitis. XIPERE will proprietary macular first review Bausch with by of XIPERE under If acetonide is leading date Bausch suspension partner the PDUFA the triamcinolone would approved it’s me. U.S. now edema be excuse first for If global October with the candidate product product a potential the with associated XIPERE U.S. XX, business. our commercial for of suprachoroidal of XIPERE is with macular and with edema and our approved, patients XXXX. eye + treatment the approved in by Health associated product, Lomb, and administration. therapy solid first health approved,

macular in a Vision, trial with this Arctic of commercializing our SCS Korea development pipeline China later with associated combines and injector. edema X South delivery clinical kinase In lead our partner is addition, of suprachoroidal that the goal for China CLS-AX, proprietary uveitis in Phase our region. axitinib in in candidate is Greater our XIPERE which inhibitor, ultimate suspension micro The tyrosine planning confirmatory begin with to in the clinical year,

patients OASIS achieved trial objectives safety in our detail, As Tom with Phase X/Xa Cohort tolerability will in discuss X AMD. wet in of our we and

of this year. now with We X the Cohort are expect month to and by data complete enrolling recruitment this end

well it offer we delivered experience wet to may durability The patients efficacy, improved AMD of as by believe the retinal suprachoroidal intravitreal suprachoroidal have injections. suprachoroidal with of the is SCS profile At we axitinib patient With Clearside, The clinical over as have injections the in of to we a opportunity frequency space, unparalleled. procedure X,XXX date. of serious disorders. pan-VEGF variety CLS-AX to reducing is injections prolong injections micro safety treatment clinical with the improve comparable in injector related our with as safety to adverse our tested no trials of multiple in and attributes events the global

our by readily clinical conducted published clinical is our technology be by In suprachoroidal the retinal physician practice AAV Biosciences. being in with well SCS wet our three in delivering two specialists. in X treatment being and two trials AMD currently injector clinical gene and SCS that injector adopted micro therapy potentially Aura retinopathy, into partners separate data office our indicates Phase REGENXBIO is micro trials addition, clinical investigators accepted utilizing REGENXBIO in injection by procedure, its is transforming Further, diabetic delivery and an we've could therapy non-surgical option. based used development based gene ongoing

continues REGENXBIO again, our Aura on progress both viral And melanoma, suprachoroidal make of is using their to programs. these As into delivering drug light micro-injector. conjugate to Biosciences Tom discuss choroidal treat meaningful shortly, SCS the will space

about future and results date forward trials. these We progress look to are from to excited the with partners our

agents to and Chief the As therapeutic Medical Ciulla, our of such, turn the Development and developing over leader partners our we we suprachoroidal call into our now review the Tom? believe will Officer Dr. of products, and programs. other for Chief partner CLS-AX in variety I Tom delivery delve space. Officer to data suprachoroidal the are of into molecule small the choice a

Thomas Ciulla

from OASIS of patients Thank Today results last to going clinical X/Xa you, of Phase wet in CLS-AX George on month positive primarily reported our safety I'm clinical everyone. afternoon and X our AMD. trial and focus Cohort good we program

tyrosine are for suprachoroidal the is potent highly program, we available inhibitor outset a axitinib space. slides related kinase of of suprachoroidal As the website supporting data CLS-AX on suspension potential delivery. at our Jenny with this to call, of micro-injector proprietary our mentioned marrying delivering into webcast. the SCS In materials via our at the are very this this benefits

we can inhibit SCS away to rapidly, able benefits potential the preliminary VEGF XIPERE compartmentalize opposed tissues the the is specifically as to suprachoroidal with only target of of receptors axitinib some the the improved in of product our we're designed with all currently benefits. chorioretinal that affected tissues for micro-injector, agents and and Importantly, our delivery bind now And VEGFA. benefit unaffected therapy to dataset candidate CLS-AX. signs from seen We've our that with first safety proprietary

five label design Phase a study As Cohort three CLS-AX in low of started clinical escalating each, and we The study of a our reminder, safety. suffering AMD. very establish approximately to patients X floor wet safety a establish of trial to and involves an from the cohorts is the in open doses tolerability X/Xa dose in of patients of order

details of the the anti-VEGF I'd Patients patient a Patients our a two to diagnosis of injections. Now, the walk received have like of wet AMD, prior trial. they've you minimum journey in for through sub includes our with therapy. testing, despite trial, have multiple screened, visual standard like and three a corneal suprachoroidal patients design it monitored center. then patients the of are active and disease for imaging a monthly that patient controlled anti-VEGF assessed dose potentially One eligible which I doses that dose What is center optimally vascularization ultimately reading returns, acuity for have Once to deemed an which confirms later, receives by fashion. of this of The receives in months. same allows is about undergoes trial Patients aflibercept, assess a the patient crossover reading assessments, eligibility. the the month single been CLS-AX. independent us masked

same average how injections, with the are injections the year XX received and the after patient's one-month and average screening. We patients treatment performed CLSXAX. assess On with was X, anti-VEGF treatment X and age patients treating on how to then each aflibercept In able in highly first prior prior the experience. compare patients with to one-month after XX perform average, had Cohort

components CLS-AX. with we're serious each no most we through of were me signs Let lidocaine the related Starting suspension emergent subconjunctival no fibrillation injection. were data anesthetic safety importantly, vitreous to haemorrhage, as assessed dispersion of adverse haze, met. the pressure assessed subconjunctival no that stopping the treatment that one for two events, and events be pleased the study there of walk There were Atrial unrelated you with summary One adverse CLS-AX. or of monitoring with report rules signals, safety, to were trial. There vasculitis, of the were to important and intraocular to inflammation, intravitreal

related best visual visual acuity XX XX. important outcomes to of in baseline improved, worsened average, One CLS-AX observed acuity, letters. acuity. administration, letters], corrected to receiving the range corrected by aflibercept, changes best within In for with letters, then to to X, of best now main three at worsened with patients patients body the they change improved entire visual on mean [XX Therefore the after a and prior corrected no dose, three of six score Moving we for contrast, month treated a on – corrected more three the analysis P-Value month receiving aflibercept. all of with Cohort letters. indicating was X.XXX. Post significant was This X.X acuity by four there was hoc letters, statistically X.X that In improvement or five best visual main CLS-AX patients six in six one with after patients the

start CST. thickness that creates I effect a average with on just microns value words, are subfield to and normal CST this they the like here if prior essentially macula, a of other to is In improve. Regarding floor CLS-AX. unlikely patient had XXX highlight of patients central with receiving would values, normal main to a

important stable low Durability treatment Cohort Importantly, these the post especially CLS-AX. dose X signs we one treatment and CLS-AX. durability saw an given CST our primary we by component in the the that is plan of potential main month experienced were patients, of was encouraged of starting in highly

loss point We greater determine and/or therapy. by best at increase XX include the vision measured XX patients have These macular a in hemorrhage. more in a need threatening visual additional CST from acuity criteria any letters if or than three trial, to an of microns,

are With receiving including or visual I'd like we vision acuity the to trial, corrected measurement, the in emphasize assessing CLS-AX. at that the from patient's point after best aflibercept any best

which in likely on As safety. are a patients is result, more our be focused to retreated trial,

Cohort of X X one At require by patients Importantly, two one retreating patients after treatment. four required the At CLS-AX, three months, treatment. letters. X vision no or not by improved, patients at months, month, one with these patients actually did and required their letters, in XX% two patients, In additional additional two receiving aflibercept.

we X tenfold a these fold X This now compared period increase X.X longer the With is X, Cohort of extension And increase Cohort and is X.X dose. advanced data. Cohort X In Cohort study ultimately, the a of expect X.X which X, dose the results to at patients adding milligram. Cohorts time. we're a over over X three-month dose also milligrams, follow of X to Cohort to have a from a we

As very we're George in X complete recruitment expect and for the progress month. pleased Cohort to mentioned, this with enrollment

We of programs, data of expect their and utilizing to programs to report trials gene end as from efficacy, Phase advance both to mentioned, the delivery their year. tolerability the continues X agent George partner RGX-XXX. the their by of therapy evaluating clinical SCS REGENXBIO of and micro-injector safety, suprachoroidal X our respect Cohort With

The severe earnings first patients report the their wet the they treatment. are AMD quarter who three Cohorts all AAVIATE second In with of in entitled of trial trial. is anti-VEGF targeting treatment announcement yesterday, to their responsive

they For scientific place of X take society to report will the September Cohort from at retina that XX data will year. X, this October interim meeting

completed And for interim XXXX. they in positive quarter in Cohort to patients antibodies. dosing For data who neutralizing report expect X, the Cohort they've are of X, for fourth

The Phase X entitled a trial clinical for the trial retinopathy, of treatment is diabetic RGX-XXX second altitude.

RGX-XXX in completed of XXXX. fourth For REGENXBIO retinopathy this REGENXBIO and that of the in expects They enrollment in which X, have Cohort who antibodies. trial, patients enrollment report diabetic retinopathy their Cohort altitude, to has quarter were third reported patients also in plans data initial patients has enroll has of positive evaluate announced cohort to and X begun. patients of diabetic for neutralizing also will

to later The after before was As by this their and in forward data of previous we encouraging, continued RGX-XXX. REGENXBIO cohorts, or patients corticosteroid therapy suppressive prophylactic presentations administration will very progress immune not receive year. look

status addition, In of excited our development clinical about the very the from our and progress we're partners. programs

CFO, turn we a to Charlie Ultimately, keeping Deignan believe improve as of active the retina look the Academy the year Specialists, events. meeting more we have of with remain now Meeting, as the at may overall financial presentations tolerability over physician our the call profile, American ophthalmic updated. the American of in will community treatment our We retina meeting, industry second that Society experience as plan durable other the well a and over within Retinal and you participation society and Medical results. will CLS-AX favorable to the the to forward Ophthalmology patient I we to review half of

Charlie Deignan

Thanks, Tom.

Our will our available status. quarter in current second website. are financial our this summarize release afternoon results were on financial our and for the press published Therefore, I

Our as of the equivalents XXXX use cash quarter cash facility providing approximately and in $XX XX, aggregate approximately an million in of million. X includes proceeds total the ATM cash from quarter, of runway. June additional our This net

burn Our our are our our spends, we work the due research have quarterly obtaining operating expect on funding XIPERE. our to CLS-AX XXXX. quarter the into on in incorporated also primarily operations activities into Based is to program plans. broader Investments to and second to sufficient for cash current and our the fund plan approval of pipeline resources related

agreements. we partnership receive milestone additional include not current our under does estimate this payments Importantly, may

receive million approved, Bausch + we in approval to pre-launch $XX from to Lomb XIPERE’s milestones. and expect As up

Additionally, a in this the funding his million. nearly community Conference events closing month, X for the this the from Arctic will forward end may investor we shareholders milestone next Conference from H.C. to week. We our and to over broader the non-dilutive Thus George tomorrow million year. turn the payment of Wainwright Ophthalmology I we receive Healthcare the in interest receive support PacGrow and not back of Vision of we remarks. investment call before and will XX look participating appreciate Wedbush

George Lasezkay

wet their believe AMD of positive future multiple study for Charlie. clinical with in OASIS We companies large partnerships from fields. top the potential Clearside and recent targeting respective Thanks, our commercial well-positioned market, growth approval with XIPERE, and data is

office platform suprachoroidal in of treatment clear leader the non-surgical based into innovative space, Our drugs approach. us makes the delivery a the with reliable

range a open ask the make up we partners, as from to our execute making and potentially internal patients questions. for suffering meaningful a difference to forward continue We blinding to operator call look closely for corporate to would diseases. of broad on our now with work progress I milestones, like the

Operator

That's with, Zegbeh George from coming you. Capital Please question And begin Jallah ask CEO, our question. is Thank [Operator your Lasezkay. to Instructions] first our from ROTH Partners. [indiscernible]

Zegbeh Jallah

taking Thanks question. for my

a Just couple have here.

if being retreated. around can more one, patients study his just to first The wonder just clarify this likely statement Tom have

George Lasezkay

Tom, that? do take to you want

Thomas Ciulla

Sure, thank for you. Thanks question. the

which have measured And we loss So is within question remarks, and mentioned loss criteria, letters one about is, XX as retreatment a XX the our prepared three criteria, the of a we of I in best trial. letters. of my from measured

companies other baseline. loss XX are Some measuring from letters

the higher we So, where a in visit our trial we sets letters. had patients that of post from where start measurement at one-month of bar improve our axitinib loss

So, gain letters numerous this receiving theoretically, patients after example, could axitinib. in

only But say XX baseline. could could they'd letters, the they couple they they letters, example, and in essence, then gain, qualify lose on and than For let's worse next for retreatment. visit, be would letters a X

actually, four of if baseline. two if patients would of that's, So, in mentioned used other more have after letters retreated treated XX been month not treated. were we axitinib, at trials, have been criteria And patients not we've of loss one four or from that you they would know, those

Zegbeh Jallah

Thanks, one Tom. the details [indiscernible] X describe what extension other and can of the you can we And possibly from in period the claim is, then that? just Cohort

Thomas Ciulla

patients total for Yes, be X, both three extension an thank follow-up study plan have question axitinib and to months essentially, dosing. The that X months you following be the for for about to to Cohorts your add we'll questions. we additional post six the is after

Zegbeh Jallah

see the I encouraging year. the think the of the the mentioned readout end was durability. we Thank data did efficacy, in know one I that was of thing terms And really here for about you. but last only just expectations the is then by you

confidence of greater leverage in just and [X this to in studies? I what how and future durability three-fold] could X you wondering, So, was kind gives increase that that of designing terms result plan data you

Thomas Ciulla

Yeah, great is durability. question. question The expected about

have address we current we're that basing studies in So, this. slides preclinical corporate our and on that our deck, some

a vision and in paper. is vision Research technology. is published the the official Medline article, One in where we of ophthalmology Journals, one for and paper corporate But ARVO in orders is model peer greater we translational than reviewed of just a Rabbit from science indexed Association out slides showed the also and in our we for of ICXX receptor that magnitude our X PK going deck, several have levels to journal in the – data the months. VEGFX This

durability, I we directly is to that, I So, Rabbit of gives the multiple the model always of want months not important. – can caution a confidence question achieve get I this get when translatable correct dose. that but humans, It us it's once lot directionally we to always we know

Zegbeh Jallah

to forward from REGENXBIO. on all Thanks, to team the looking Congrats this and the Tom. progress data

Thomas Ciulla

you interest. Thank your for

Operator

next go Annabel And question Stifel. ahead. Please of our is from Samimy

Annabel Samimy

my thanks taking question. Hi, for

question, months can on this the X terms ideal? think, just this other you for? you actually might you higher what or traffic for about in monitoring what You commercially? you I level patients, there foot you aiming terms want touched months of is the XX words, What a with be and of guess in of do patients? ophthalmologists in it think in whether durability last is durability when spot, – are What of drug doses, sweet are expect but

George Lasezkay

think some directional that? talked Tom, mean, please want about this And answer I or you to you that discuss guidance. question I do we've can internally. give

Thomas Ciulla

Sure.

most desired complicated the know, you more So is, durability. And, that. but, the the much is simple it's possible, answer about you question than want know, you

have agents know, significant be of durability. currently. you we than than will months first all, think, I several And, there better approved no anything very better are have that what

now returning and assessment the is involves model physician – realize right aspect that, the right low. to rather model involves for examination, retina the bar possible is other to retreatment. the practice the patients I So, then now think And

go it's to So, not you current completely to to going say, be, know, done, you the realistic patients. system current it and one really and not disruptive have, from may you're system be may the with for know, all it

think burden. less model. retina decrease for will doctor months to And, be current setting. three it's think very you patients where be could would But treatment to coming So, would this more four sweet to between months, I anyway the spot think certainly be the than the current months back meaningful X the I I reassessment. to in anything And somewhere know, you disruptive also, X practice

that aspect evidence is is also pan-VEGF a and there about efficacy our is pan-VEGF inhibitor current therapy that The have it over addition and clinically inhibition. potential other benefits focused VEGFA some pre-clinically may in

potential a So, have efficacy know, with favorable ability, what current targeting multi-master you we're outcomes in so we be also profile. for far obviously, but to better safety therapy seems

Annabel Samimy

treatment Okay, you're but you in or are you again as this comment, patients, is control with going high dose forward, you're trial, the about design? be thinking with program how trial] the placebo, also, great. looking at next you to [future that, as how like know, going it you're looking And far X/X with a bar, appropriate and thinking And patients Phase last the when so your active you about combination be to non-inferiority? experienced following I superiority guess, an an naive for think find able this trial? you to Obviously, how know, seems to about going are trial,

George Lasezkay

company discussions can at trial but design those I in that am the around in Tom the anything says that haven't say plan the Before we're some that some would our to color least we really final [Phase Xb]. discussions that, Those you issues, that, sure worked out on are of related give on having. I Tom are ongoing just

Thomas Ciulla

[thunder]. my It's dependent. data stole very You

we're And the lowest to only our inform you Cohorts effect. and the don’t dose and we obviously, data know, Cohort X treatment durability, know, You about be from the at looking better X. trial. next I a have have going X, idea potential that'll

it having be data dependent. So, now, those will and discussions ultimately, you we're as George mentioned, know,

Annabel Samimy

Right, thank you.

Operator

Securities. And our ask Please of Wedbush from Andreas your next question Argyrides is question.

Andreas Argyrides

[Liana]. Thank everyone. Andreas is taking Good afternoon, Thanks questions. for on you, for operator. our This

a patient one a it baseline – help you here, Just patients color how Could the and to Cohort when enrollment on Cohort bit Cohort inform the that? X? comes the X, of Thanks. provide characteristics, those did quick little of X in X’s Cohort

George Lasezkay

you. to up that’s Tom

Thomas Ciulla

best of this Yeah. Thanks question. in patient didn't know, X. criteria and is being Generally you explored. change as trials, for any to not for populations, change We Cohort the the clinical it's enrollment

our criteria very we consistent. kept So,

have Our persistent patients to X. criteria any we in didn't are very, requiring, of have went change you essentially the center and criteria as Cohort strict activity terms of BCVA know, prior into on to and reading treatment, have patients based we have

Andreas Argyrides

based results my let able for results from rephrase some a you So, maybe the and I from you responses? you ask where but two, that where patient criteria, responders able were the correctly in Not had just me X, were subjects of the on that perspective, regard? enrich six, so selection durable question, [indiscernible] the Cohort Cohort that you who number patient to X, as saw the to enrich

Thomas Ciulla

not we the the sure same, really sites kept And criteria. I'm we to dosing. clinical Well, the pretty except everything are you didn't you much keep criteria, know, the tried the mean trial enriching, for by same. same, but what We the change

Andreas Argyrides

back you, the queue. Thanks. I'll I Thank guys. Okay. appreciate jump in that.

Operator

go Yi is from question And our Chen, ahead. H.C. Please Wainwright. next

Yi Chen

my the loan preference can IPO [indiscernible] Bausch can comment taking once and for for various [indiscernible] I if insurance you payers? question. how Thank you Health know approved, access you don't quickly of potential commercial

George Lasezkay

really the directed that's better Yeah, question a But thanks the team. for question. Bausch to

product this into, to we team of not little they're forward those about accessing you're will think on they what and deal have formularies, have something with best – with going but abolish, all addressed affairs not issues. the We that's questions that, product, with terms and questions asking, bit the FDA, move with, do med dealing injection and training, closely once know gotten related are but as to of reimbursement the product NDA with dealing their we're not the worked of of to all be a in that to very them really and really we preparation we kind their the approved, especially really

that's So, them. directed think to I a Bausch best question,

Yi Chen

that Got to so? they pursue have do still Bausch for long do how once it. indicated approved, indications [XIPERE] the would option and Has other they

George Lasezkay

discussions had information speaking have those – you're but about we on of pursue we've them, contract indications. additional indications, under been with exchange indications, that additional They no about the them If have there, any agreement with time. at there's decisions been an indication the we made license can

No So, when there's do timing the right indications. an have on timing if They no do or but restrictions reasonable there. restrictions to on obligation they to them of that, in terms pursue additional not that. would

Yi Chen

Got you. it. Thank

Operator

[Operator Instructions] let's And now continue.

Next of JMP is Please go Jon ahead. Wolleben Securities.

Jon Wolleben

progress on taking and for thanks congrats Hey, the question. the

George Lasezkay

Jon. Thanks

Jon Wolleben

CLS-AX come Tom for dry patients might fluid, going [BCBA] or in we're like increases not would motivation? open being label if wondering we're change function mechanistically some in expect benefits? comment, One give [BCBA] these visual just maybe a with be wondering just this and on seeing at you looking the a when is the or patient decrease the when in pretty Or you on what data, eyes, would of perhaps to this to see could here

George Lasezkay

you can Tom? Okay, go

Thomas Ciulla

asked question, great Jon. you it. I'm That’s glad

clinical that with central well correlates trials subfield You especially visual it's known acuity, thickness know, wet in really among AMD. retina poorly

really disease suggest correlate but think I so, doesn't with it acuity. And activity, visual may

recruiting function change we experience. the the not And, that you in it's up see is against CST. we’re surprising, a that are didn't fact so, patients know, who a too that floor especially of we much because have treatment a And effect, really

corrected XX So, very know, on have study I visual them other have, best entry. expected letters wouldn't at to acuity, The on thick the average maculars. you hand,

there. range, there roughly effect, [indiscernible] there. room And floor there's the a you room so there's of little may that's, be in for though a bit So for [XX.XX] even improvement know, improvement still

think more explains little need we obviously, more a So, of and to corroborate I this. patients bit data And that it.

Jon Wolleben

or that you helpful. wait third you're talk cohort That's the is sooner? about dosing do it. to second when something see to you that able data can have Can cohort, the start to Got happen

Thomas Ciulla

And the out should the just next the if our then We've X. monitoring you hope as [sense study to through four when Well, you data done of the end you the cohort know, been third plan that the with safety – trial. readily the trial march fact is we guess beginning And of know, of] discussing can at have year. the start a be we you We timelines, run Cohort would to that by committee. month year.

Jon Wolleben

Okay. And within the one you've mentioned I you maybe those? from what last on can us Appreciate eligible and REGENX if it I milestones of development may? one, the you're received? XIPERE payments guys. the that think the Charlie of approval, potential for remind what already context And triggers

Thomas Ciulla

to milestones we've milestones, as I total REGENX the anything be Charlie, than the other know that that available. disclose might don't done

Charlie Deignan

can give on in That's all the That's right. we sales development out Yeah, we've, you million XXX that. know, there's $XX million in detail additional milestones, about and then milestones.

Jon Wolleben

from And our next Company. Okay, question ahead. Serge Please Needham from again. thanks go is Belanger &

Serge Belanger

afternoon good thanks and Hi, questions. my for taking

it one on the an CLS-AX CST, Tom, important like just how to you're the questions patient to on follow-up a criteria. related the sounds and tweaking ability not have CST for show the entry for to First impact prior it is

So, couple able of next in here? you'll cohorts some differences you be expect the to show

Thomas Ciulla

Well, great thanks for the follow-up a question. It's question.

You know, area we're you know, know, you well. obviously, there's leakage that as multiple we've we're anatomic looking We're CST, to in parameters, trials, well, as at and other [indiscernible]. looking angiographic AMD at looked parameters in area, wet CMV at area, traditionally addition parameters. And, region

nice, comprehensive convenient. assessments. really quick. anatomic have it's It's non-invasive, is it's a of CST we'll So, battery because

to picture best tell You know, with it's doesn't, respect quite acuity. know, precise, the corrected the but it whole really visual you

Serge Belanger

payment the clinical in in guess Arctic Vision prepared development? there's for next Okay. curious one X to guess of George. I comments associated was And just China, I that of you your XIPERE the that with starting trial advancement mentioned Phase milestone any the if start

George Lasezkay

milestone macular associated There we've currently is, year set agreement. Phase been associated It’s with one but able this disclosed with that amount. a that but that, in is uveitis. X, that's not the the disclose start to the we've nothing There a edema there to But to not. is due nature of

Serge Belanger

helpful. Thanks. Okay. That’s

Operator

question-and-answer And that I At like this would the over our it session. concludes to CEO, point, George turn Lasezkay. to

George Lasezkay

you thank on this forward Clearside for now updating And us the you. progress the look the call. continued interest future. you Operator, call you joining disconnect and our you our to in on all in company may Thank Thank appreciate afternoon. we your We all.

Operator

And you call everyone this you. Thank conference for with concludes Thank today's Clearside. participation.

all disconnect. now may You

Clearside Biomedical (CLSD) 11 Aug 212021 Q2 Earnings call transcript